AC Immune SA (ACIU)Healthcare | Biotechnology | Lausanne, Switzerland | NasdaqGM
3.01 USD
-0.06
(-1.954%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.01 Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:55 a.m. EDT
Despite deteriorating fundamentals and_neg_1M sales, ACIU is experiencing a massive speculative divergence. The stock is decoupling from its earnings reality on the short end; while the P/E suggests a value trap and burn rate is high, the options flow is overwhelmingly bullish on a 2x price swing, driven likely by the positive news surrounding the Eli Lilly Tau program. This is a high-risk momentum trade riding a specific catalyst gap, not a fundamental value play. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.175707 |
| AutoETS | 0.175797 |
| AutoARIMA | 0.175874 |
| MSTL | 0.181378 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.768 |
| Excess Kurtosis | -0.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.117 |
| Revenue per Share | 0.035 |
| Market Cap | 306,338,464 |
| Forward P/E | 4.92 |
| Beta | 1.63 |
| Website | https://www.acimmune.com |
As of April 19, 2026, 12:55 a.m. EDT: Call activity is heavily skewed strike-up, with significant Open Interest (OI) and volume concentrated at 5.0 and 7.5 level (OTM), suggesting bulls are positioning for a significant move to these levels (approx. +66% to +149% from ATM). Put OI is low, with notable interest only at deep OTM strikes for 2026-11-20 expiry. This gamma-side bias implies speculators are expecting a 100%+ rally relative to current price, while downside hedging is minimal.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0337837 |
| Address1 | Building B |
| Address2 | EPFL Innovation Park |
| All Time High | 19.97 |
| All Time Low | 1.43 |
| Ask | 3.05 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 350,920 |
| Average Daily Volume3 Month | 297,995 |
| Average Volume | 297,995 |
| Average Volume10Days | 350,920 |
| Beta | 1.63 |
| Bid | 2.97 |
| Bid Size | 1 |
| Book Value | 0.5629806 |
| City | Lausanne |
| Compensation As Of Epoch Date | 1,703,980,800 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.01 |
| Current Ratio | 1.021 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.16 |
| Day Low | 2.97 |
| Debt To Equity | 10.117 |
| Earnings Timestamp | 1,773,405,000 |
| Earnings Timestamp End | 1,777,465,800 |
| Earnings Timestamp Start | 1,777,465,800 |
| Ebitda | -67,470,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.138 |
| Enterprise To Revenue | 59.257 |
| Enterprise Value | 211,724,464 |
| Eps Current Year | -0.4 |
| Eps Forward | 0.6122125 |
| Eps Trailing Twelve Months | -0.9 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 41 21 345 91 20 |
| Fifty Day Average | 2.9341 |
| Fifty Day Average Change | 0.07590008 |
| Fifty Day Average Change Percent | 0.025868267 |
| Fifty Two Week Change Percent | 103.378365 |
| Fifty Two Week High | 4.0 |
| Fifty Two Week High Change | -0.99 |
| Fifty Two Week High Change Percent | -0.2475 |
| Fifty Two Week Low | 1.45 |
| Fifty Two Week Low Change | 1.56 |
| Fifty Two Week Low Change Percent | 1.075862 |
| Fifty Two Week Range | 1.45 - 4.0 |
| Financial Currency | CHF |
| First Trade Date Milliseconds | 1,474,637,400,000 |
| Float Shares | 38,392,830 |
| Forward Eps | 0.6122125 |
| Forward P E | 4.9165936 |
| Free Cashflow | -41,761,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 90 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -52,863,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.37893 |
| Held Percent Institutions | 0.25521 |
| Implied Shares Outstanding | 101,773,573 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. |
| Long Name | AC Immune SA |
| Market | us_market |
| Market Cap | 306,338,464 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_22309440 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -70,447,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 305,320,719 |
| Number Of Analyst Opinions | 4 |
| Open | 3.12 |
| Operating Cashflow | -69,262,000 |
| Operating Margins | -42.6213 |
| Payout Ratio | 0.0 |
| Phone | 41 21 345 91 21 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.01 |
| Post Market Time | 1,776,456,604 |
| Previous Close | 3.07 |
| Price Eps Current Year | -7.525 |
| Price Hint | 4 |
| Price To Book | 5.3465433 |
| Price To Sales Trailing12 Months | 85.737045 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.973 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -1.9544 |
| Regular Market Day High | 3.16 |
| Regular Market Day Low | 2.97 |
| Regular Market Day Range | 2.97 - 3.16 |
| Regular Market Open | 3.12 |
| Regular Market Previous Close | 3.07 |
| Regular Market Price | 3.01 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 265,057 |
| Return On Assets | -0.22349001 |
| Return On Equity | -0.89653 |
| Revenue Growth | -0.703 |
| Revenue Per Share | 0.035 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 101,773,573 |
| Shares Percent Shares Out | 0.0291 |
| Shares Short | 2,964,467 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,316,141 |
| Short Name | AC Immune SA |
| Short Percent Of Float | 0.060700003 |
| Short Ratio | 11.21 |
| Source Interval | 15 |
| Symbol | ACIU |
| Target High Price | 12.10449 |
| Target Low Price | 7.0141153 |
| Target Mean Price | 9.117328 |
| Target Median Price | 8.675353 |
| Total Cash | 91,412,000 |
| Total Cash Per Share | 0.921 |
| Total Debt | 4,541,000 |
| Total Revenue | 3,573,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.8539 |
| Two Hundred Day Average Change | 0.15610003 |
| Two Hundred Day Average Change Percent | 0.054697093 |
| Type Disp | Equity |
| Volume | 265,057 |
| Website | https://www.acimmune.com |
| Zip | 1,015 |